Oral second generation antihistamines in allergic rhinitis;Orale antihistaminika der 2. Generation bei allergischer rhinitis

Laryngo- Rhino- Otologie

Volumn 84, Issue 1, 2005, Pages 30-41

  Riechelmann, Herbert ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Histamine; Histamine H1 antagonists, non sedating; Nasal mucosa; Rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; CLEMASTINE; DIMETINDENE; EBASTINE; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; HISTAMINE RECEPTOR; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; PROMETHAZINE; TERFENADINE;

ALLERGIC RHINITIS; ALLERGY; BRONCHUS MUSCLE; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; EDEMA; ENDOTHELIUM CELL; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MAST CELL; MENTAL PERFORMANCE; NASAL PRURITUS; NEUROGENIC INFLAMMATION; NOSE ALLERGY; NOSE MUCOSA; NOSE SECRETION; PARASYMPATHETIC NERVE; PHARMACODYNAMICS; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; REBOUND; REFLEX; REVIEW; SEDATION; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; SNEEZING; TACHYPHYLAXIS; TRIGEMINAL NERVE; TRIGEMINAL PARASYMPATHETIC REFLEX;

ADMINISTRATION, ORAL; ADULT; ANTI-ALLERGIC AGENTS; CETIRIZINE; CHILD; CONJUNCTIVITIS, ALLERGIC; CONTROLLED CLINICAL TRIALS; FEMALE; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; LORATADINE; MALE; NASAL MUCOSA; PREGNANCY; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H1; RECEPTORS, HISTAMINE H2; RHINITIS, ALLERGIC, SEASONAL; TIME FACTORS;

EID: 13644261423     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826000     Document Type: Review

References (119)

1. Rasp G. Therapie der allergischen Rhinitis. Laryngorhinootologie 1993; 72: 373-378
2. Albegger K. Symptomatische Therapie der allergischen Rhinitis. Laryngorhinootologie 1990; 69: 613-620
3. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: 147-334
4. Klimek L, Eggers G. Olfactory dysfunction in allergic rhinitis is related to nasal eosinophilic inflammation. J Allergy Clin Immunol 1997; 100: 158-164
5. Wilken JA, Berkowitz R, Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 372-380
6. Marshall PS, O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol 2000; 84: 403-410
7. Marshall PS, O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002; 64: 684-691
8. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71: 121-126
9. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med 2001; 43: 64-71
10. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000; 21: 7-13
11. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy 1997; 52: 12-18
12. Gerth van Wijk R, Mulder PG, Dieges PH. Nasal provocation with histamine in allergic rhinitis patients: clinical significance and reproducibility. Clin Exp Allergy 1989; 19: 293-298
13. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289-297
14. Okuda M, Watase T, Mezawa A, Liu CM. The role of leukotriene D4 in allergic rhinitis. Annals of Allergy 1988; 60: 537-540
15. Doyle WJ, Boehm S, Skoner DP. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol 1990; 86: 924-935
16. Wang DY, Hanotte F, DeVos C, Clement P. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 2001; 56: 339-343
17. Austin CE, Foreman JC. Acoustic rhinometry compared with posterior rhinomanometry in the measurement of histamine- and bradykinin-induced changes in nasal airway patency. British Journal of Clinical Pharmacology 1994; 37: 33-37
18. Numata T, Konno A, Yamakoshi T, Hanazawa T, Terada N, Nagata H. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999; 108: 467-473
19. Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H, Kohno S. Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model: contribution of dilated mucosal blood vessels. Jpn J Pharmacol 2001; 86: 170-182
20. Howarth P, Walsh S, Robinson C. The comparative nasal effects of prostaglandin D2 in normal and rhinitic subjects. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 449-452
21. MacGlashan D, Jr. Histamine: A mediator of inflammation. J Allergy Clin Immunol 2003; 112: 53-59
22. Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol 2003; 111: 24-32
23. Nilsson G, Costa JJ, Metcalfe DD. Mast cells and basophils. In: Gallin JI, Snyderman R (Hrsg.). Inflammation - basic principles and clinical correlates. Philadelphia, PA: Lippincott Williams & Wilkins, 1999: 97-117
24. Marone G, Granata F, Spadaro G, Genovese A, Triggiani M. The histamine-cytokine network in allergic inflammation. J Allergy Clin Immunol 2003; 112: 83-88
25. Ash AS, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27: 427-439
26. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385-390
27. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-837
28. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49: 253-278
29. Leurs R, Blandina P, Tedford C, Timmerman H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 1998; 19: 177-183
30. Raible DG, Lenahan T, Fayvilevich Y, Kosinski R, Schulman ES. Pharmacologic characterization of a novel histamine receptor on human eosinophils. Am J Respir Crit Care Med 1994; 149: 1506-1511
31. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275: 36781-36786
32. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003; 112: 15-22
33. Milligan G, Bond RA, Lee M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 1995; 16: 10-13
34. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-498
35. Simons FER. Antihistamines. In: Adkinson NF, Middleton E, (Hrsg.). Middleton's allergy - principles & practice. St. Louis: Mosby, 2003: 834-869
36. Shelton D, Eiser N. Histamine receptors in the human nose. Clinical Otolaryngology 1994; 19: 45-49
37. Togias A. H1-receptors: localization and role in airway physiology and in immune functions. J Allergy Clin Immunol 2003; 112: 60-68
38. Togias A, Proud D, Kagey-Sobotka A, Norman P, Lichtenstein L, Naclerio R. The effect of a topical tricyclic antihistamine on the response of the nasal mucosa to challenge with cold, dry air and histamine. J Allergy Clin Immunol 1987; 79: 599-604
39. Mygind N. Nasal inflammation and anti-inflammatory treatment. Semantics or clinical reality. Rhinology 2001; 39: 61-65
40. Konno A, Togawa K, Fujiwara T. The mechanisms involved in onset of allergic manifestations in the nose. Eur J Respir Dis 1983; 64: 155-166
41. Baroody FM, Wagenmann M, Naclerio RM. Comparison of the secretory response of the nasal mucosa to methacholine and histamine. J Appl Physiol 1993; 74: 2661-2671
42. Hirata N, Takeuchi K, Ukai K, Jin C, Yoshida T, Sakakura Y. Expression and localization of histamine H2 receptor messenger RNA in human nasal mucosa. J Allergy Clin Immunol 1999; 103: 944-949
43. Okayama M, Baraniuk JN, Hausfeld JN, Merida M, Kaliner MA. Characterization and autoradiographic localization of histamine H1 receptors in human nasal turbinates. J Allergy Clin Immunol 1992; 89: 1144-1150
44. Howarth P. Clinical nasal decongestant activity with oral antihistamines. Clinical Experimental Allergy Reviews 2002; 2: 101-106
45. Bockman CS, Zeng W. Histamine receptor type coupled to nitric oxide-induced relaxation of guinea-pig nasal mucosa. Auton Autacoid Pharmacol 2002; 22: 269-276
46. Imai A, Nabe T, Mizutani N, Sakurai H, Takenaka H, Kohno S. Involvement of nitric oxide in pollen-induced biphasic nasal blockage in sensitised guinea pigs. Eur J Pharmacol 2001; 423: 63-70
47. Silkoff PE, Roth Y, McClean P, Cole P, Chapnik J, Zamel N. Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis. Ann Otol Rhinol Laryngol 1999; 108: 368-372
48. Maniscalco M, Sofia M, Carratu L, Higenbottam T. Effect of nitric oxide inhibition on nasal airway resistance after nasal allergen challenge in allergic rhinitis. Eur J Clin Invest 2001; 31: 462-466
49. Dear JW, Ghali S, Foreman JC. Attenuation of human nasal airway responses to bradykinin and histamine by inhibitors of nitric oxide synthase. Br J Pharmacol 1996; 118: 1177-1182
50. Havas TE, Cole P, Parker L, Oprysk D, Ayiomamitis A. The effects of combined H1 and H2 histamine antagonists on alterations in nasal airflow resistance induced by topical histamine provocation. J Allergy Clin Immunol 1986; 78: 856-860
51. Secher C, Kirkegaard J, Borum P, Maansson A, Osterhammel P, Mygind N. Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations. J Allergy Clin Immunol 1982; 70: 211-218
52. Wood-Baker R, Lau L, Howarth PH. Histamine and the nasal vasculature: the influence of H1 andH2-histamine receptor antagonism. Clin Otolaryngol 1996; 21: 348-352
53. Mizutani N, Nabe T, Sasaki K, Takenaka H, Kohno S. Nasal hyperresponsiveness to histamine induced by repetitive exposure to cedar pollen in guinea-pigs. Eur Respir J 1999; 14: 1368-1375
54. American Academy of Allergy and Immunology. The use of antihistamines in patients with asthma. J Allergy Clin Immunol 1988; 82: 481-482
55. Gonzalez M, Estes K. Pharmacokinetic overview of oral second-generation H1 antihistamines. International Journal of Clinical Pharmacology and Therapeutics 1998; 36: 292-300
56. Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001; 15: 853-870
57. Stoll W. Otogener Schwindel. Differenzierung und Therapie. Laryngorhinootologie 1993; 72: 311-315
58. Liu Q, Horio Y, Fujimoto K, Fukui H. Does the [3H]mepyramine binding site represent the histamine H1 receptor? Re-examination of the histamine H1 receptor with quinine. J Pharmacol Exp Ther 1994; 268: 959-964
59. Benavides J, Schoemaker H, Dana C, Claustre Y, Delahaye M, Prouteau M et al. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittelforschung 1995; 45: 551-558
60. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56 (Suppl 65): 7-13
61. Frossard N, Benabdesselam O, Purohit A, Mounedji N, Pauli G. Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol 2000; 14: 409-413
62. Frossard N, Melac M, Benabdesselam O, Pauli G. Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol 1998; 80: 61-65
63. Purohit A, Melac M, Pauli G, Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003; 56: 388-394
64. Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24h. Br J Clin Pharmacol 2002; 53: 250-254
65. Purohit A, Duvernelle C, Melac M, Pauli G, Frossard N. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol 2001; 86: 387-392
66. Purohit A, Duvernelle C, Melac M, Benabdesselam O, Pauli G, Frossard N. Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity. Eur J Clin Pharmacol 1999; 55: 589-592
67. Grant JA, Danielson L, Rihoux JP, DeVos C. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999; 54: 700-707
68. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990; 86: 540-547
69. Juhlin L. A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. Allergy 1995; 50: 24-30
70. Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003; 52: 424-427
71. Bousquet J, Czarlewski W, Cougnard J, Danzig M, Michel FB. Changes in skin-test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis. Allergy 1998; 53: 579-585
72. Braunstein G, Malaquin F, Fajac I, Melac M, Frossard N. Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis. Br J Clin Pharmacol 1992; 33: 445-448
73. van Steekelenburg J, Clement PA, Beel MH. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002; 57: 346-350
74. Crawford WW, Klaustermeyer WB, Lee PH, Placik IM. Comparative efficacy of terfenadine, loratadine, and astemizole in perennial allergic rhinitis. Otolaryngol Head Neck Surg 1998; 118: 668-673
75. Baroody FM, Lim MC, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Effects of loratadine and terfenadine on the induced nasal allergic reaction. Arch Otolaryngol Head Neck Surg 1996; 122: 309-316
76. Bousquet J, Lebel B, Chanal I, Morel A, Michel FB. Antiallergic activity of H1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988; 82: 881-887
77. Persi L, Demoly P, Harris AG, Tisserand B, Michel FB, Bousquet J. Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. J Allergy Clin Immunol 1999; 103: 591-594
78. Simons KJ, Simons FER. Clinical pharmacology of H1 antihistamines. In: Simons FER (Hrsg.). Histamine and H1-antihistamines in allergic disease. New York: Marcel Dekker, 2002: 141ff
79. Bousquet J, Chanal I, Skassa-Brociek W, Lemonier C, Michel FB. Lack of subsensitivity to loratadine during long-term dosing during 12 weeks. J Allergy Clin Immunol 1990; 86: 248-253
80. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002; 23: 391-398
81. Wiseman LR, Faulds D. Ebastine. A review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996; 51: 260-277
82. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 1504-1509
83. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077-1080
84. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109: 956-961
85. van Cauwenberge P, Wang D. Antihistamines and nasal blockage. Allergy 1997; 40: 35-38
86. Wang D, Clement P, Smitz J. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta Otolaryngol 1996; 116: 91-96
87. Ciprandi G, Tosca MA, Ricca V, Passalacqua G, Riccio AM, Bagnasco M et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 1997; 27: 1160-1166
88. Ciprandi G, Ricca V, Tosca MA, Landi M, Passalacqua G, Canonica GW. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy 1999; 54: 358-365
89. Simons FE, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol 2002; 110: 777-783
90. Marone G. Milestones in the biology and pharmacology of histamine H1-receptor antagonists. Allergy 1997; 34: 7-13
91. Gelfand EW, Appajosyula S, Meeves S. Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research. Curr Med Res Opin 2004; 20: 73-81
92. Bensch GW, Nelson HS, Borish LC. Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. Ann Allergy Asthma Immunol 2002; 88: 457-462
93. Di Lorenzo G, Gervasi F, Drago A, Esposito Pellitteri M, Di Salvo A, Cosentino D et al. Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitics. Clin Exp Allergy 1999; 29: 1367-1377
94. Taborda-Barata L, Jacobson M, Walker S, Njuki F, Ying S, Randev P et al. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clin Exp Allergy 1996; 26: 68-78
95. Sienra-Monge JJ, Gazca-Aguilar A, Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther 1999; 6: 149-155
96. Simons FE, Johnston L, Simons KJ. Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. Pediatr Allergy Immunol 2000; 11: 116-119
97. Simons FE. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol 1999; 104: 433-440
98. Spicak V, Dab I, Hulhoven R, Desager JP, Klanova M, De Longueville M et al. Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin Pharmacol Ther 1997; 61: 325-330
99. Pariente-Khayat A, Rey E, Dubois MC, Vauzelle-Kervroedan F, Pons G, d'Athis P et al. Pharmacokinetics of cetirizine in 2- to 6-year-old children. Int J Clin Pharmacol Ther 1995; 33: 340-344
100. Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf 2001; 24: 119-147
101. Schatz M. H1-antihistamines in pregnancy and lactation. In: Simons FER (Hrsg.). Histamine and H1-antihistamines in allergic disease. New York: Marcel Dekker, 2002: 421ff
102. Loebstein R, Lalkin A, Addis A, Costa A, Lalkin I, Bonati M et al. Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. J Allergy Clin Immunol 1999; 104: 953-956
103. Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997; 78: 183-186
104. Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111: 479-483
105. Diav-Citrin O, Shechtman S, Aharonovich A, Moerman L, Arnon J, Wajnberg R et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111: 1239-1243
106. Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines. In: Simons FER (Hrsg.). Histamine and H1-antihistamines in allergic disease. New York: Marcel Dekker, 2002: 389ff
107. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non- sedating" antihistamines: four prescription-event monitoring studies in general practice. Bmj 2000; 320: 1184-1186
108. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106: 201-205
109. Polzehl D, Keck T, Riechelmann H. Analyse der Effektivität der subkutanen Immuntherapie mit Hausstaubmilbenextrakten bei Erwachsenen mit allergischer Rhinitis und/oder Asthma bronchiale. Laryngorhinootologie 2003; 82: 272-280
110. Nielsen LP, Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med 2003; 2: 55-65
111. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. British Medical Journal 1998; 317: 1624-1629
112. Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003; 112: 1021-1031
113. Moinuddin R, deTineo M, Maleckar B, Naclerio RM, Baroody FM. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004; 92: 73-79
114. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826-1832
115. Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 126-132
116. Mygind N, Dahl R, Bisgaard H. Leukotrienes, leukotriene receptor antagonists, and rhinitis. Allergy 2000; 55: 421-424
117. Tonnesen P, Mygind N. Nasal challenge with serotonin and histamine in normal persons. Allergy 1985; 40: 350-353
118. Pipkorn U, Andersson M. Topical dermal anaesthesia inhibits the flare but not the weal response to allergen and histamine in the skin-prick test. Clin Allergy 1987; 17: 307-311
119. Sicherer SH, Eggleston PA. EMLA cream for pain reduction in diagnostic allergy skin testing: effects on wheal and flare responses. Ann Allergy Asthma Immunol 1997; 78: 64-68